Streetbeat News

Price Targets

APRE

HC Wainwright & Co. has reiterated its Buy rating on Aprea Therapeutics (NASDAQ:APRE) and maintained a $20 price target, as stated by analyst Joseph Pantginis.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:50 pm

VTYX

Wells Fargo analyst Derek Archila maintains an Overweight rating on Ventyx Biosciences (NASDAQ:VTYX) but lowers the price target from $16 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:48 pm

BITF

HC Wainwright & Co. analyst Mike Colonnese has reiterated a Buy rating on Bitfarms (NASDAQ:BITF) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:48 pm

POWI

Northland Capital Markets has upgraded Power Integrations (NASDAQ:POWI) from Market Perform to Outperform, with a new price target of $80.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:47 pm

CLDX

Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Celldex Therapeutics (NASDAQ:CLDX) and raises the price target from $35 to $37.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:45 pm

MNDY

Piper Sandler has reiterated its Overweight rating on Monday.Com (NASDAQ:MNDY) and raised the price target from $270 to $300.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:45 pm

MNDY

Needham analyst Scott Berg maintains a Buy rating on Monday.Com (NASDAQ:MNDY) and raises the price target from $250 to $300.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:44 pm

KYMR

Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Kymera Therapeutics (NASDAQ:KYMR) and raises the price target from $30 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:43 pm

CHDN

Churchill Downs Inc (NASDAQ: CHDN) received an upgrade from Bank of America analyst Shaun C. Kelley, who raised the price target from $145 to $155. The upgrade is driven by strong organic growth, a promising development pipeline, and the upcoming opening of a new gaming resort in Northern Virginia. Kelley believes Churchill Downs can achieve sustainable double-digit growth, setting it apart from its peers.

Portfolio Pulse from Chris Katje

August 12, 2024 | 5:43 pm

TSHA

Needham analyst Gil Blum maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) but lowers the price target from $7 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 5:42 pm